-
EP4593961
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4593961
| EP4593961 - TREATMENT OF DRUG-RESISTANT HEPATOCELLULAR CARCINOMA [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 22.01.2026 Database last updated on 09.04.2026 | |
| Former | Request for examination was made Status updated on 04.07.2025 | ||
| Former | The international publication has been made Status updated on 06.04.2024 | ||
| Former | unknown Status updated on 13.10.2023 | Most recent event Tooltip | 23.01.2026 | First examination report | Applicant(s) | For all designated states Alentis Therapeutics AG Hegenheimermattweg 167A 4123 Allschwil / CH | For all designated states Université de Strasbourg 4, rue Blaise Pascal 67081 Strasbourg / FR | For all designated states Institut National de la Santé et de la Recherche Médicale 7 rue Watt 75013 Paris / FR | For all designated states Hôpitaux Universitaires de Strasbourg (HUS) 1, Place de l'Hôpital 67000 Strasbourg / FR | [2025/32] | Inventor(s) | 01 /
IACONE, Roberto 4123 Basel / CH | 02 /
TOSO, Alberto 4051 Basel / CH | 03 /
MEYER, Markus KJ 79395 Neuenburg am Rhein / DE | 04 /
BAUMERT, Thomas Fredy 67000 Strasbourg / FR | 05 /
DUONG, Hong Tuan 68320 Fortschwihr / FR | [2025/32] | Representative(s) | Haseltine Lake Kempner LLP Cheapside House 138 Cheapside London EC2V 6BJ / GB | [2025/32] | Application number, filing date | 23783380.1 | 02.10.2023 | [2025/32] | WO2023EP77233 | Priority number, date | US202263377861P | 30.09.2022 Original published format: US 202263377861 P | [2025/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2024069009 | Date: | 04.04.2024 | Language: | EN | [2024/14] | Type: | A1 Application with search report | No.: | EP4593961 | Date: | 06.08.2025 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.04.2024 takes the place of the publication of the European patent application. | [2025/32] | Search report(s) | International search report - published on: | EP | 04.04.2024 | Classification | IPC: | A61P35/00, A61K31/44, C07K16/28 | [2025/32] | CPC: |
A61P35/00 (EP,US);
C07K16/28 (EP,US);
A61K31/44 (EP);
C07K16/2818 (EP,US);
A61K2039/507 (US);
C07K2317/21 (EP);
C07K2317/24 (EP,US);
C07K2317/565 (US);
C07K2317/73 (EP);
C07K2317/76 (EP)
(-)
| C-Set: |
A61K31/44, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/32] | Title | German: | BEHANDLUNG VON ARZNEIMITTELRESISTENTEM HEPATOZELLULÄREM KARZINOM | [2025/32] | English: | TREATMENT OF DRUG-RESISTANT HEPATOCELLULAR CARCINOMA | [2025/32] | French: | TRAITEMENT D'UN CARCINOME HÉPATOCELLULAIRE RÉSISTANT AUX MÉDICAMENTS | [2025/32] | Entry into regional phase | 25.04.2025 | National basic fee paid | 25.04.2025 | Designation fee(s) paid | 25.04.2025 | Examination fee paid | Examination procedure | 25.04.2025 | Examination requested [2025/32] | 25.04.2025 | Date on which the examining division has become responsible | 13.11.2025 | Amendment by applicant (claims and/or description) | 21.01.2026 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 10.10.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD] WO2017162678 (INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) et al.) | [A] EP3070103 (INST HOSPITALIER UNIVERSITAIRE DE STRASBOURG et al.) | [A] ROEHLEN NATASCHA ET AL: "OS-2190 A humanized Claudin-1 specific monoclonal antibody for treatment of hepatocellular carcinoma", 11 June 2021 (2021-06-11), XP093047142, Retrieved from the Internet | [A] YAU THOMAS ET AL: "Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 1, 13 December 2021 (2021-12-13), pages 77 - 90, XP086907720, DOI: 10.1016/S1470-2045(21)00604-5 DOI: http://dx.doi.org/10.1016/S1470-2045(21)00604-5 | [A] VAN DOORN DIEDERICK J. ET AL: "Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview", PHARMACEUTICALS, vol. 14, no. 1, 1 January 2021 (2021-01-01), pages 3, XP093047215, Retrieved from the Internet DOI: http://dx.doi.org/10.3390/ph14010003 | [IP] ROEHLEN NATASCHA ET AL: "Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment", JOURNAL OF HEPATOLOGY, vol. 78, no. 2, 1 February 2023 (2023-02-01), AMSTERDAM, NL, pages 343 - 355, XP093072423, ISSN: 0168-8278, DOI: 10.1016/j.jhep.2022.10.011 DOI: http://dx.doi.org/10.1016/j.jhep.2022.10.011 | by applicant | US8008449 | WO2010034812 | WO2016146809 | WO2021094469 | WO2017162678 | EP1167389 | US6627439 | WO2014132307 | WO2015014659 | WO2015014357 | US8354509 | US8900587 | WO2006121168 | WO2008156712 | WO2012145493 | WO2009014708 | WO03099196 | WO2009114335 | WO2011161699 | US6808710 | US7488802 | US8168757 | US2016272708 | WO2015112900 | WO2015112800 | WO2014206107 | WO2015035606 | WO2015085847 | WO2014179664 | WO2017020291 | WO2017020858 | WO2016197367 | WO2017024515 | WO2017025051 | WO2017123557 | WO2016106159 | WO2014194302 | WO2017040790 | WO2017133540 | WO2017132827 | WO2017024465 | WO2017025016 | WO2017106061 | WO2017019846 | WO2017132825 | US2015079109 | US7943743 | WO2013173223 | US8217149 | WO2011066389 | WO2013079174 | WO2013181634 | WO2016149201 | WO2017034916 | LLOVET JM ET AL., NAT REV DIS PRIMERS, vol. 7, no. 6, 2021 | FINN RS ET AL., N ENGL J MED, vol. 382, 2020, pages 1894 - 905 | CALDERARO J ET AL., J HEPATOL, vol. 71, 2019, pages 616 - 30 | QIN S ET AL., SIGNAL TRANSDUCT TARGET THER, vol. 5, 2020, pages 228 | SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2000, COLD SPRING HARBOR LABORATORY PRESS | AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1992, GREENE PUBLISHING ASSOCIATES | "NCBI", Database accession no. NP_066924.1 | KABAT, E.A. ET AL.: "Sequences of Protein of immunological interest", 1991, US DEPARTMENT OF HEALTH AND HUMAN SERVICES | LEFRANC. M.P. ET AL., BIOMOLECULES, vol. 4, no. 4, December 2014 (2014-12-01), pages 1102 - 1139 | WANG ET AL., CANCER IMMUNOL RES, vol. 2, no. 9, 2014, pages 846 - 56 | YAMASHITA ET AL., J. PHARMACOL. EXP. THER., vol. 353, no. 1, 2015, pages 112 - 118 | "Methods in Enzymol.", vol. 34, 1974, ACADEMIC PRESS, article "Affinity Techniques. Enzyme Purification: Part B" | WILCHEKBAYER, ANAL. BIOCHEM., vol. 171, 1988, pages 1 - 32 | LLOVET J.M. ET AL., N. ENGL. J. MED., vol. 359, 2008, pages 378 - 390 | LIU L ET AL., CANCER RES., vol. 66, 2006, pages 1 1851 - 11858 | SI-YANG LIU ET AL., J. HEMATOL. ONCOL, vol. 10, 2017, pages 136 | SI-YANG LIU ET AL., J. HEMATOL. ONCOL., vol. 10, 2017, pages 136 | HERBST ET AL., J CLIN ONCOL, vol. 31, 2013 | ZHANG ET AL., CELL DISCOV, vol. 7, no. 3, March 2017 (2017-03-01) | CROUCHET E ET AL., NAT COMMUN, vol. 12, 2021, pages 5525 | JUHLING F ET AL., GUT, vol. 70, 2021, pages 157 - 69 | SONG Y ET AL., J EXP CLIN CANCER RES, vol. 37, 2018, pages 109 |